< Current issue
Dermatopathology: Practical & Conceptual July - September 2003
What ever happened to BANS—and why?
A. Bernard Ackerman, M.D.
Naghmeh Yousefzadeh, M.D.
The history of BANS as conveyed through synopses of publications about it
Addendum 1 (The American Journal of Dermatopathology 1982 Oct;4(5):387–9.)
1. Day CL, Jr., Sober AJ, Kopf AW,
A prognostic model for clinical stage I melanoma of the upper extremity. The importance of anatomic subsites in predicting recurrent disease.
2. Kopf AW, Rigel D, Bart RS,
Factors related to thickness of melanoma. Multifactorial analysis of variables correlated with thickness of superficial spreading malignant melanoma in man.
J Dermatol Surg Oncol
3. Day CL, Jr., Sober AJ, Kopf AW,
A prognostic model for clinical stage I melanoma of the trunk. Location near the midline is not an independent risk factor for recurrent disease.
Am J Surg
4. Day CL. Jr., Mihm MC Jr., Sober AJ,
Prognostic factors for melanoma patients with lesions 0.761.69 mm in thickness. An appraisal of "thin" level IV lesion.
5. Woods JE, Taylor WF,
Is the BANS concept for malignant melanoma valid?
Am J Surg
6. Rogers GS, Kopf AW, Rigel DS,
Influence of anatomic location on prognosis of malignant melanoma: attempt to verify the BANS model.
J Am Acad Dermatol
7. Blois MS, Sagebiel RW, Tuttle MS,
Judging prognosis in malignant melanoma of the skin: A problem of inference over small data sets.
8. Cascinelli N, Vaglini M,
BANS. A cutaneous region with no prognostic significance in patients with melanoma.
This site is made possible in part by:
Copyright © Derm101.com. All Rights Reserved.